Current treatment of juvenile rheumatoid arthritis

Norman Todd Ilowite

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Prognostic factors in juvenile rheumatoid arthritis (JRA) include polyarticular onset, polyarticular disease course, and rheumatoid factor positivity; in the systemic onset subtype, persistence of systemic features at 6 months after onset confers a worse prognosis. Timely diagnosis and appropriate aggressive treatment of patients with poor prognostic features improve quality of life and outcome. After nonsteroidal anti-inflammatory drugs, methotrexate is the most commonly used second-line agent. However, approximately one third of patients do not respond to methotrexate adequately. Randomized, placebo-controlled, clinical trials in patients with JRA are few, but one such trial with the tumor necrosis factor inhibitor etanercept shows that this drug is effective and well-tolerated. Other recently approved agents for rheumatoid arthritis, including infliximab, leflunomide, celecoxib, and rofecoxib, have not been adequately studied in pediatric patients, and the role of these agents in children with JRA remains to be determined.

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalPediatrics
Volume109
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Juvenile Arthritis
Celecoxib
leflunomide
Methotrexate
Rheumatoid Factor
Proxy
Pharmaceutical Preparations
Rheumatoid Arthritis
Anti-Inflammatory Agents
Therapeutics
Randomized Controlled Trials
Tumor Necrosis Factor-alpha
Placebos
Quality of Life
Pediatrics

Keywords

  • Antirheumatic agents
  • Disease-modifying antirheumatic drugs
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Current treatment of juvenile rheumatoid arthritis. / Ilowite, Norman Todd.

In: Pediatrics, Vol. 109, No. 1, 2002, p. 109-115.

Research output: Contribution to journalArticle

Ilowite, Norman Todd. / Current treatment of juvenile rheumatoid arthritis. In: Pediatrics. 2002 ; Vol. 109, No. 1. pp. 109-115.
@article{38a5021bb393439f9855b2af3a80d94b,
title = "Current treatment of juvenile rheumatoid arthritis",
abstract = "Prognostic factors in juvenile rheumatoid arthritis (JRA) include polyarticular onset, polyarticular disease course, and rheumatoid factor positivity; in the systemic onset subtype, persistence of systemic features at 6 months after onset confers a worse prognosis. Timely diagnosis and appropriate aggressive treatment of patients with poor prognostic features improve quality of life and outcome. After nonsteroidal anti-inflammatory drugs, methotrexate is the most commonly used second-line agent. However, approximately one third of patients do not respond to methotrexate adequately. Randomized, placebo-controlled, clinical trials in patients with JRA are few, but one such trial with the tumor necrosis factor inhibitor etanercept shows that this drug is effective and well-tolerated. Other recently approved agents for rheumatoid arthritis, including infliximab, leflunomide, celecoxib, and rofecoxib, have not been adequately studied in pediatric patients, and the role of these agents in children with JRA remains to be determined.",
keywords = "Antirheumatic agents, Disease-modifying antirheumatic drugs, Tumor necrosis factor",
author = "Ilowite, {Norman Todd}",
year = "2002",
doi = "10.1542/peds.109.1.109",
language = "English (US)",
volume = "109",
pages = "109--115",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Current treatment of juvenile rheumatoid arthritis

AU - Ilowite, Norman Todd

PY - 2002

Y1 - 2002

N2 - Prognostic factors in juvenile rheumatoid arthritis (JRA) include polyarticular onset, polyarticular disease course, and rheumatoid factor positivity; in the systemic onset subtype, persistence of systemic features at 6 months after onset confers a worse prognosis. Timely diagnosis and appropriate aggressive treatment of patients with poor prognostic features improve quality of life and outcome. After nonsteroidal anti-inflammatory drugs, methotrexate is the most commonly used second-line agent. However, approximately one third of patients do not respond to methotrexate adequately. Randomized, placebo-controlled, clinical trials in patients with JRA are few, but one such trial with the tumor necrosis factor inhibitor etanercept shows that this drug is effective and well-tolerated. Other recently approved agents for rheumatoid arthritis, including infliximab, leflunomide, celecoxib, and rofecoxib, have not been adequately studied in pediatric patients, and the role of these agents in children with JRA remains to be determined.

AB - Prognostic factors in juvenile rheumatoid arthritis (JRA) include polyarticular onset, polyarticular disease course, and rheumatoid factor positivity; in the systemic onset subtype, persistence of systemic features at 6 months after onset confers a worse prognosis. Timely diagnosis and appropriate aggressive treatment of patients with poor prognostic features improve quality of life and outcome. After nonsteroidal anti-inflammatory drugs, methotrexate is the most commonly used second-line agent. However, approximately one third of patients do not respond to methotrexate adequately. Randomized, placebo-controlled, clinical trials in patients with JRA are few, but one such trial with the tumor necrosis factor inhibitor etanercept shows that this drug is effective and well-tolerated. Other recently approved agents for rheumatoid arthritis, including infliximab, leflunomide, celecoxib, and rofecoxib, have not been adequately studied in pediatric patients, and the role of these agents in children with JRA remains to be determined.

KW - Antirheumatic agents

KW - Disease-modifying antirheumatic drugs

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0036140928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036140928&partnerID=8YFLogxK

U2 - 10.1542/peds.109.1.109

DO - 10.1542/peds.109.1.109

M3 - Article

C2 - 11773549

AN - SCOPUS:0036140928

VL - 109

SP - 109

EP - 115

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -